Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hoth Therapeutics ( (HOTH) ) has provided an update.
On August 5, 2025, Hoth Therapeutics held its annual shareholder meeting where key decisions were made, including the re-election of board members and the ratification of Withum Smith+Brown as the independent accounting firm for 2025. Additionally, shareholders approved an amendment to the 2022 Omnibus Equity Incentive Plan to increase the reserved shares for issuance, and advisory votes on executive compensation were conducted.
The most recent analyst rating on (HOTH) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Hoth Therapeutics stock, see the HOTH Stock Forecast page.
More about Hoth Therapeutics
Hoth Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies for dermatological and immunological conditions.
Average Trading Volume: 1,173,135
Technical Sentiment Signal: Buy
Current Market Cap: $17.24M
For detailed information about HOTH stock, go to TipRanks’ Stock Analysis page.